Best Practices for Treatment of Invasive Methicillin-Susceptible Staphylococcus aureus Infections: The Case for Oxacillin.
Vanderbilt Vaccine Research Program, Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
James B
JB
Wood
Vanderbilt Vaccine Research Program, Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Isaac P
IP
Thomsen
Vanderbilt Vaccine Research Program, Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.
C Buddy
CB
Creech
Division of Pediatric Infectious Diseases, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri.
Jason G
JG
Newland
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D010068:Oxacillin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D010068:Oxacillin
Staphylococcus aureus; cefazolin; inoculum effect; invasive staphylococcal disease; oxacillin